Search

Displaying results 5741 - 5750 of 10000 in total
  1. Drug

    Mizolastine

    go.drugbank.com/drugs/DB12523
    Approved

    Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

    Products: MIZOLEN 10 MG TABLETAS DE LIBERACION PROLONGADA
  2. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  3. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.

  4. Drug

    Bufotenine

    go.drugbank.com/drugs/DB01445
    ExperimentalIllicit

    A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics.

    Synonyms: 3-[2-(dimethylamino)ethyl]indol-5-ol
  5. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation). … Fulzerasib has a monoisotopic molecular weight of 630.22 Da.

  6. Drug

    Brimarafenib

    go.drugbank.com/drugs/DB21706
    Investigational

    Brimarafenib is under investigation in clinical trial NCT04249843 (Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors). … Brimarafenib has a monoisotopic molecular weight of 482.12 Da.

  7. Drug

    Faxeladol

    go.drugbank.com/drugs/DB20529
    Investigational

    Effect of Food on it). … Faxeladol has a monoisotopic molecular weight of 233.18 Da.

  8. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

  9. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  10. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones.